Abstract
Background Several biomarkers of acute kidney injury (AKI) have been examined for their ability to predict AKI earlier than serum creatinine. Few studies have focused on using kidney biomarkers to better predict major adverse kidney events (MAKE), an increasingly used composite outcome in critical care nephrology research.
Methods Single-center prospective study collecting blood and urine samples from critically ill patients with AKI KDIGO stage 2 or above, and matched controls from a single, tertiary care intensive care unit. Samples were collected at 24-48 hours after AKI diagnosis (cases) or ICU admission (controls), 5-7 days later, and 4-6 weeks following discharge for AKI patients. The primary outcome of interest was MAKE at hospital discharge.
Results Serum/urinary neutrophil gelatinase-associated lipocalin, serum/urinary cystatin C, and urinary kidney injury molecule-1 early in the AKI or ICU course were all significantly higher in patients with MAKE compared to those not experiencing MAKE at hospital discharge. Serum cystatin C, and to a lesser extent serum NGAL, significantly improved upon a clinical prediction model of MAKE as assessed by the area under the receiver operating characteristic curve.
Patients without MAKE experienced a greater decline in serum NGAL from initial measurement to second measurement than those patients experiencing MAKE.
Conclusion Early measures of kidney biomarkers in critically ill patients are associated with MAKE. This relationship appears to be greatest with serum NGAL and cystatin C, which display additive utility to a clinical prediction model. Trending serum NGAL may also have utility in predicting MAKE.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by the University of Texas Southwestern Medical Center O Brien Kidney Research Core Center (P30 DK079328) and the National Center for Advancing Translational Sciences (UL1TR001105). The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health or the University of Texas Southwestern. JN is currently supported by an Early Career Pilot Grant from the National Center for Advancing Translational Sciences (NCATS) National Institutes of Health (NIH) through Grant UL1 TR001998. RT is supported by the NIH (R21 HL145424 UH3 DK114870). OM is supported by the NIH (R01 DK091392 R01 DK092461 the George O Brien Kidney Research Center P30 DK 07938) the Charles and Jane Pak Center Endowed Professor Collaborative Research Support and Innovative Research Support
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol was approved by the Institutional Review Board at University of Texas Southwestern.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Support: This work was supported, in part, by the University of Texas Southwestern Medical Center O’Brien Kidney Research Core Center (P30 DK079328-06) and the National Center for Advancing Translational Sciences (UL1TR001105). The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health or the University of Texas Southwestern. JN is currently supported by an Early Career Pilot Grant from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), through Grant UL1 TR001998. RT is supported by the NIH (R21-HL145424, UH3-DK114870). OM is supported by the NIH (R01-DK091392, R01-DK092461, the George O’Brien Kidney Research Center P30-DK-07938), the Charles and Jane Pak Center Endowed Professor Collaborative Research Support and Innovative Research Support.
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request
